JP7805285B2 - ３，５－二置換ベンゼンアルキニル化合物とｍｅｋ阻害剤とを用いた癌治療法 - Google Patents

３，５－二置換ベンゼンアルキニル化合物とｍｅｋ阻害剤とを用いた癌治療法

Info

Publication number
JP7805285B2
JP7805285B2 JP2022514133A JP2022514133A JP7805285B2 JP 7805285 B2 JP7805285 B2 JP 7805285B2 JP 2022514133 A JP2022514133 A JP 2022514133A JP 2022514133 A JP2022514133 A JP 2022514133A JP 7805285 B2 JP7805285 B2 JP 7805285B2
Authority
JP
Japan
Prior art keywords
salt
dose
compound
administered
per dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022514133A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021206167A1 (https=
JPWO2021206167A5 (https=
Inventor
洋 平井
和明 松岡
晃敬 三浦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiho Pharmaceutical Co Ltd
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of JPWO2021206167A1 publication Critical patent/JPWO2021206167A1/ja
Publication of JPWO2021206167A5 publication Critical patent/JPWO2021206167A5/ja
Application granted granted Critical
Publication of JP7805285B2 publication Critical patent/JP7805285B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022514133A 2020-04-10 2021-04-09 ３，５－二置換ベンゼンアルキニル化合物とｍｅｋ阻害剤とを用いた癌治療法 Active JP7805285B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020071355 2020-04-10
JP2020071355 2020-04-10
PCT/JP2021/015032 WO2021206167A1 (ja) 2020-04-10 2021-04-09 ３，５－二置換ベンゼンアルキニル化合物とｍｅｋ阻害剤とを用いた癌治療法

Publications (3)

Publication Number Publication Date
JPWO2021206167A1 JPWO2021206167A1 (https=) 2021-10-14
JPWO2021206167A5 JPWO2021206167A5 (https=) 2022-12-27
JP7805285B2 true JP7805285B2 (ja) 2026-01-23

Family

ID=78024029

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022514133A Active JP7805285B2 (ja) 2020-04-10 2021-04-09 ３，５－二置換ベンゼンアルキニル化合物とｍｅｋ阻害剤とを用いた癌治療法

Country Status (5)

Country Link
US (1) US20230165862A1 (https=)
EP (1) EP4134081A4 (https=)
JP (1) JP7805285B2 (https=)
TW (1) TW202200146A (https=)
WO (1) WO2021206167A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116768903B (zh) * 2023-06-20 2025-05-09 河北康泰药业有限公司 一种吡咯并嘧啶衍生物及其制备方法、药物组合物和应用
CN116789673B (zh) * 2023-06-20 2025-07-29 河北康泰药业有限公司 一种吡咯并嘧啶衍生物及其制备方法、药物组合物和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015008839A1 (ja) 2013-07-18 2015-01-22 大鵬薬品工業株式会社 Ｆｇｆｒ阻害剤の間歇投与用抗腫瘍剤

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3811775B2 (ja) 2000-07-19 2006-08-23 ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー ４−ヨードフェニルアミノベンズヒドロキサム酸の酸素化エステル
KR100984595B1 (ko) 2002-03-13 2010-09-30 어레이 바이오파마 인크. Ｍｅｋ 억제제로서의 ｎ3 알킬화 벤즈이미다졸 유도체
CN1905873A (zh) 2003-11-19 2007-01-31 阵列生物制药公司 Mek的杂环抑制剂及其使用方法
SI1761528T1 (sl) 2004-06-11 2008-06-30 Japan Tobacco Inc 5-amino-2,4,7-triokso-3,4,7,8-tetrahidro-2H-pirido(2,3-D)pirimidinski derivati in sorodne spojine za zdravljenje raka
ZA200703912B (en) 2004-10-20 2008-09-25 Serono Lab 3-arylamino pyridine derivatives
CA2618218C (en) 2005-07-21 2015-06-30 Ardea Biosciences, Inc. N-(arylamino)-sulfonamide inhibitors of mek
SI1934174T1 (sl) 2005-10-07 2011-08-31 Exelixis Inc Inhibitorji MEK in postopki za njihovo uporabo
JP6860919B2 (ja) * 2015-11-19 2021-04-21 国立大学法人金沢大学 間葉系ｋｒａｓ変異型がん治療剤
EP3424505A4 (en) * 2016-03-04 2019-10-16 Taiho Pharmaceutical Co., Ltd. PREPARATION AND COMPOSITION FOR THE TREATMENT OF MALIGNANT TUMORS
KR102811888B1 (ko) * 2017-09-08 2025-05-27 에프. 호프만-라 로슈 아게 암의 진단 및 치료 방법

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015008839A1 (ja) 2013-07-18 2015-01-22 大鵬薬品工業株式会社 Ｆｇｆｒ阻害剤の間歇投与用抗腫瘍剤

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BOCKORNY, B et al.，RAS-MAPK Reactivation Facilitates Acquired Resistance in FGFR1-Amplified Lung Cancer and Underlies a Rationale for Upfront FGFR-MEK Blockade，Molecular Cancer Therapeutics，2018年，17(7)，1526-1539
KALYUKINA, M et al.，TAS-120 Cancer Target Binding:Defining Reactivity and Revealing the First Fibroblast Growth Factor Receptor 1(FGFR1) Irreversible Structure，ChemMedChem，2019年，14，494-500
MERIC-BERNSTAM, F et al.，Efficacy of TAS-120, an irreversible fibroblast growth factor receptor (FGFR) inhibitor, in cholangiocarcinoma patients with FGFR pathway alternations who were previously treated with chemotherapy and other FGFR inhibitors，Annals of Oncology，2018年，29 (Supplement 5)，v100-v110

Also Published As

Publication number Publication date
WO2021206167A9 (ja) 2021-11-18
EP4134081A4 (en) 2024-05-01
US20230165862A1 (en) 2023-06-01
JPWO2021206167A1 (https=) 2021-10-14
TW202200146A (zh) 2022-01-01
EP4134081A1 (en) 2023-02-15
WO2021206167A1 (ja) 2021-10-14

Similar Documents

Publication Publication Date Title
TWI607754B (zh) 醫藥組合
JP2022520079A (ja) Ｔｎｏ１５５及びｋｒａｓｇ１２ｃ阻害剤を含む医薬組合せ
AU2019200881A1 (en) Combination therapy
TW202011966A (zh) 用pi3k抑制劑gdc-0077治療癌症之方法
UA125216C2 (uk) Комбінована терапія
AU2020253054B2 (en) FGFR tyrosine kinase inhibitors for the treatment of urothelial carcinoma
CN119733053A (zh) Kras g12c抑制剂与米托蒽醌的药物组合及其用途
TW202027736A (zh) 用PI3Kα抑制劑及二甲雙胍治療癌症之方法
KR20200014298A (ko) Her2 양성 암의 치료
US20140348819A1 (en) Methods of Treating Cancer
CN110652514A (zh) 第三代egfr抑制剂的制药用途
JP2016522247A (ja) 組合せ医薬
EP2750675A1 (en) Synergistic combinations of pi3k- and mek-inhibitors
JP7574184B2 (ja) 悪性腫瘍の治療方法
JP7805285B2 (ja) ３，５－二置換ベンゼンアルキニル化合物とｍｅｋ阻害剤とを用いた癌治療法
CN113194952A (zh) Hdm2-p53相互作用抑制剂和bcl2抑制剂的组合及其治疗癌症的用途
MX2013014151A (es) Metodos para tratar el mesotelioma con un compuesto inhibidor de la pi3k.
JP2025019298A (ja) 線維芽細胞増殖因子受容体阻害剤と内分泌療法との併用による内分泌療法が適用される腫瘍の治療及び予防方法
JP2020023497A (ja) 組合せ医薬
CN114728003B (zh) 治疗b细胞恶性肿瘤的阿卡替尼和卡帕塞替尼的治疗组合
TWI872311B (zh) 一種吡啶并[1,2-a]嘧啶酮類似物的應用
US20070135444A1 (en) Treatment of neuroblastoma
RU2816126C2 (ru) Способ лечения злокачественной опухоли
CN102781444A (zh) 用于治疗肝细胞癌的抗肿瘤剂或手术后辅助化学治疗剂
WO2024240025A1 (zh) 一种联合用药物组合物及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221108

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240313

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250225

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250421

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250626

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250909

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251209

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251223

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260113

R150 Certificate of patent or registration of utility model

Ref document number: 7805285

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150